ALK gene copy number gain and its clinical significance in hepatocellular carcinoma

Table 2 Association between anaplastic lymphoma kinase copy number gain and clinicopathological characteristics of hepatocellular carcinoma patients n (%)

Characteristics	Total cases	ALK/CNG		P value
		Positive (28 cases)	Negative (185 cases)
Age (yr)
< 49	105	12 (11.4)	93 (88.6)	0.465
≥ 49	108	16 (14.8)	92 (85.2)
Sex
Female	17	3 (17.6)	14 (82.4)	0.843
Male	196	25 (12.8)	171 (87.2)
Grade
I + II	116	12 (10.3)	104 (89.7)	0.186
III + IV	97	16 (16.5)	81 (83.5)
Stage
I + II	174	21 (12.1)	153 (87.9)	0.326
III + IV	39	7 (17.9)	32 (82.1)
Relapse
No	83	13 (15.7)	70 (84.3)	0.385
Yes	130	15 (11.5)	115 (88.5)
AFP (ng/mL)
< 400	125	19 (15.2)	106 (84.8)	0.290
≥ 400	88	9 (10.2)	79 (89.8)
Child-Pugh- classification
A	195	25 (12.8)	170 (87.2)	0.922
B + C	18	3 (16.7)	15 (83.3)
HBV DNA
Positive	113	17 (15.0)	96 (85.0)	0.383
Negative	100	11 (11.0)	89 (89.0)
Postoperative platelet count
< 100 × 109/L	35	2 (5.7)	33 (94.3)	0.250
≥ 100 × 109/L	178	26 (14.6)	152 (85.4)

ALK/CNG: Anaplastic lymphoma kinase copy number gain; AFP: Alpha fetoprotein; HBV: Hepatitis B virus.